6533b85bfe1ef96bd12bbfba

RESEARCH PRODUCT

Immunohistochemical expression of ubiquitin and telomerase in cervical cancer

Llombart Bosch AntonioToro De Méndez Morelva

subject

AdultTelomerasePathologymedicine.medical_specialtyBiologíaClone (cell biology)Uterine Cervical NeoplasmsCervix UteriBiologyPathology and Forensic MedicineUbiquitinBiomarkers TumormedicineHumansPapillomaviridaeTelomeraseMolecular BiologyAgedCervical cancerTissue microarrayUbiquitinCancerArtículosCell BiologyGeneral MedicineMiddle AgedFacultad de Farmacia y Bioanálisismedicine.diseaseImmunohistochemistryImmunohistochemical expressionEpidermoid carcinomaTissue Array AnalysisCervical cancerbiology.proteinImmunohistochemistryFemale

description

Artículo publicado en: Virchows Arch (2009) 455:235–243. DOI 10.1007/s00428-009-0818-7 Ubiquitin and telomerase immunohistochemical expression patterns in cervical cancer were compared with normal cervical tissue samples. Eighty-one cervical cancer cases and 22 normal exo–endocervical tissue were examined with polyclonal antibody for ubiquitin and 44G12 clone for telomerase using tissue microarrays. The results were interpreted using a semiquantitative scale The average age of patients was 50.67 years. The most frequent histological types were moderately differentiated epidermoid carcinoma (43.5%), according to the degree of differentiation, and endocervical adenocarcinoma (42.1%). Immunohistochemical findings were as follows: 98.7% of cervical cancers showed immunoexpression for ubiquitin and 52.6% for telomerase. Statistically significant differences were found in tumor immunoreactivity when compared with control tissue (p<0.0007) for both biomarkers. There was no significant difference in biomarker expression at different histological types of tumors, although telomerase was less expressed in endocervical adenocarcinoma. Our findings confirmthat abnormal immunoexpression pattern of ubiquitin and telomerase is common in HPVpositive cervical cancer, indicating the existence of an intense degradation of proteins, subsequent cellular immortalization and maintenance of the malignant phenotype. 235-243 tmorelva@ula.ve antonio.llombart@uv.es

https://doi.org/10.1007/s00428-009-0818-7